Companies › Sun Pharmaceutical Industries
8 active drug programs in 13 registered trials: 5 Phase 3, 5 Phase 2, 2 Phase 1, 1 Phase 4; Immunology, Oncology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Clascoterone Androgen Receptor antagonist | AR | Phase 4 | Acne Vulgaris | – |
| Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA Aminolevulinic acid prodrug for photodynamic therapy; converted to protoporphyrin IX for p | PPOX | Phase 3 | Actinic Keratosis | Jan 2027 |
| Tildrakizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque Psoriasis | Feb 2027 |
| Deuruxolitinib Phosphate (CTP-543) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | Alopecia Areata | May 2027 |
| GL0034 GLP-1 receptor agonist | GLP1R | Phase 2 | Type II Diabetes Mellitus | Apr 2027 |
| Abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 2 | Metastatic Cancer | Dec 2027 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Metastatic Cancer | Dec 2027 |
| Levulan Kerastick (reformulated) 5-aminolevulinic acid (ALA) prodrug for photodynamic therapy | PPOX | Phase 1 | Actinic Keratosis (AK) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04314531 | Tildrakizumab | Phase 3 | Active Psoriatic Arthritis | Immunology | Jun 2025 |
| NCT06425900 | Clascoterone | Phase 4 | Acne Vulgaris | Immunology | Mar 2026 |
| NCT07385547 | GL0034 | Phase 1 | Type II Diabetes Mellitus | Metabolic and endocrine | Sep 2026 |
| NCT07729579 | Levulan Kerastick (reformulated) | Phase 1 | Actinic Keratosis (AK) | Immunology | Dec 2026 |
| NCT07144852 | Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA | Phase 3 | Actinic Keratosis | Oncology | Jan 2027 |
| NCT06611163 | Tildrakizumab | Phase 3 | Moderate to Severe Genital Psoriasis | Immunology | Feb 2027 |
| NCT07282743 | GL0034 | Phase 2 | Type II Diabetes Mellitus | Metabolic and endocrine | Apr 2027 |
| NCT03898479 | Deuruxolitinib Phosphate (CTP-543) | Phase 2 | Alopecia Areata | Immunology | May 2027 |
| NCT05422911 | Abiraterone acetate | Phase 2 | Metastatic Cancer | Oncology | Dec 2027 |
| NCT05422911 | Enzalutamide | Phase 2 | Metastatic Cancer | Oncology | Dec 2027 |
| NCT07133308 | Deuruxolitinib Phosphate (CTP-543) | Phase 3 | Alopecia Areata | Immunology | May 2028 |
| NCT04991116 | Tildrakizumab | Phase 3 | Psoriatic Arthritis | Immunology | Dec 2028 |
| NCT03997786 | Tildrakizumab | Phase 2 | Moderate-to-severe Chronic Plaque Psoriasis | Immunology | Aug 2031 |
PPOX (2) AR (2) JAK1 (1) JAK2 (1) JAK3 (1) TYK2 (1) GLP1R (1) IL12B (1) IL23A (1) CYP17A1 (1)
AbbVie Pfizer Incyte Alfasigma Takeda LEO Pharma Eisai Suzhou Zelgen Biopharmaceuticals Johnson & Johnson (Janssen) Novartis
Chong Kun Dang Pharmaceutical Sunshine Guojian Pharmaceutical (Shanghai) Ganzhou Hemay Pharmaceutical Antengene Biologics Molecure
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.